Business Wire

WA-AMAZON

Share
Amazon Announces Investment in Nature-Based Carbon Removal Solutions in Brazil with The Nature Conservancy

As part of its efforts to support global solutions to the climate crisis, Amazon (NASDAQ: AMZN) today announced the launch of the Agroforestry and Restoration Accelerator in partnership with The Nature Conservancy , a global environmental organization. The Accelerator will create a more sustainable source of income for thousands of local farmers in the Brazilian Amazonian state of Pará, while also restoring native rainforests and fighting climate change by naturally trapping and storing carbon.

According to the Intergovernmental Panel on Climate Change, nature-based solutions have a critical role to play in avoiding the worst effects of climate change. Governments and the private sector can both reduce carbon emissions and remove carbon from the atmosphere by investing in nature-based solutions at scale. The Agroforestry and Restoration Accelerator is one such carbon removal project, and part of Amazon’s commitment to meeting The Climate Pledge , which the company co-founded with Global Optimism . Signatories to the Pledge commit to reaching net-zero carbon by 2040—10 years ahead of the Paris Agreement.

As part of its commitment to meet The Climate Pledge, Amazon is first and foremost continuing to innovate and invest in decarbonizing its businesses. The company has purchased 100,000 electric delivery vehicles, and is the largest corporate buyer of renewable energy in the world. Amazon is also investing in nature-based solutions outside of its value chain through the Right Now Climate Fund , which supports the Accelerator and other projects to restore degraded lands in ways that improve the livelihoods of local communities and remove carbon from the atmosphere. Additionally, through the recently announced LEAF Coalition —a public-private initiative to mobilize at least $1 billion to protect the world’s tropical forests—Amazon and other partners are working to curb tropical deforestation, reducing the amount of carbon emitted in the atmosphere.

“Restoring the world’s forests is one of the most meaningful actions we can take right now to address climate change, and it will require innovative solutions to be successful,” said Kara Hurst, vice president of worldwide sustainability at Amazon. “We are proud to launch the Agroforestry and Restoration Accelerator in partnership with The Nature Conservancy to support solutions that prioritize high environmental integrity and strong community benefits. Amazon is looking forward to contributing our passion for innovation along with financial support to improve the livelihoods of local communities in Brazil, while helping to protect the planet for future generations.”

“Science is unequivocal in regarding natural systems as the priority for absorbing carbon from the atmosphere and the latest IPCC report underscores this,” said Christiana Figueres, co-founder of Global Optimism and former UN climate chief responsible for the Paris Agreement. “Protecting standing ecosystems and restoring degraded land are critical as carbon mitigation strategies, especially over the next decade or two. Projects that achieve this to sustain both nature and the livelihoods of the local community are invaluable to the transformation needed to thrive well beyond the climate crisis. Kudos to Amazon and The Nature Conservancy.”

Amazon’s initial investment in the Accelerator will support 3,000 farmers and restore approximately 20,000 hectares—a land mass approximately the size of the City of Seattle—within three years, removing up to 10 million metric tons of carbon dioxide from the atmosphere through 2050.

The Nature Conservancy will work together with the World Agroforestry Centre and several local civil society organizations to implement the Accelerator by helping small farmers restore degraded cattle pastures to native forest and agroforestry. The agroforestry systems will provide farmers with a sustainable source of income through the sale of cocoa and other crops. The Accelerator will also experiment with innovative ways to support farmers and nurture markets for sustainable forest-based commodities, including with digital technologies, and will advance new methodologies and satellite-based technologies for quantifying and monitoring carbon removal.

“Pará is home to 9% percent of the world’s tropical forest, but it’s facing unprecedented rates of deforestation, losing 3,300 acres every day in the last year,” said Jennifer Morris, CEO, The Nature Conservancy. “Over the last 13 years, small farms in Pará—an area where slash-and-burn agriculture can seem like the only option—were responsible for an average of 40% of the state’s deforestation. For 20 years, The Nature Conservancy has worked with small farmers, community leaders, government officials, and Indigenous peoples to identify and implement win-win solutions, like agroforestry, that help people and nature thrive. This new partnership with Amazon will allow us to provide the resources and technical assistance needed to advance this program and demonstrate that regenerative agroforestry and carbon markets are viable business models for communities in the Amazon.”

"We must join forces to achieve what may be the goal of the century: to develop our economies and safeguard people's income, while preserving and restoring the forest,” said Helder Barbalho, Governor of Pará. "The state of Pará is ready to tackle this challenge, and our strategy is clearly laid out in our Amazonia Agora plan, which commits us to being carbon free by 2036, through the reduction of deforestation and by promoting forest restoration. Investments, such as Amazon's, in sustainable agroforestry and reforestation in Pará are very welcome. This initiative will significantly benefit the state's community, natural resources, and biodiversity."

For more information on Amazon’s commitment to sustainability, visit: https://sustainability.aboutamazon.com .

About Amazon

Amazon is guided by four principles: Customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Amazon strives to be Earth’s Most Customer-Centric Company, Earth’s Best Employer, and Earth’s Safest Place to Work. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology, Amazon Studios, and The Climate Pledge are some of the things pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

About The Nature Conservancy

The Nature Conservancy is a global conservation organization dedicated to conserving the lands and waters on which all life depends. Guided by science, we create innovative, on-the-ground solutions to our world's toughest challenges so that nature and people can thrive together. We are tackling climate change, conserving lands, waters and oceans at an unprecedented scale, providing food and water sustainably and helping make cities more sustainable. Working in 72 countries and territories: 38 by direct conservation impact and 34 through partners, we use a collaborative approach that engages local communities, governments, the private sector, and other partners. To learn more, visit www.nature.org or follow @nature_press on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye